• COVID-19 and mRNA Vaccines

    Collection
     
       

    Daniel Jolley.

    7 articles.

    Created July 14, 2021, last updated 18 days ago.


    Collection: 144, Score: 32, Trend score: 0, Read count: 33, Articles count: 7, Created: 2021-07-14 02:42:11 UTC. Updated: 2021-07-14 04:00:01 UTC.

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    Collected Articles

    • N. Engl. J. Med. · Apr 2021

      Letter

      Neutralizing Activity of BNT162b2-Elicited Serum.

      Pfizer and BioNTech reported that phase 3 trials of their mRNA SARS-COV-2 vaccine showed:

      • Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose.
      • Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration.
      • Vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent.
      • Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose.
      summary

      expand abstract… or not…

    • N. Engl. J. Med. · Dec 2020

      Randomized Controlled Trial Multicenter Study

      Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. ⋯ A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

      explore more… or not…

    • Immunity · Dec 2020

      Comparative Study

      SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.

      The deployment of effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to eradicate the coronavirus disease 2019 (COVID-19) pandemic. Many licensed vaccines confer protection by inducing long-lived plasma cells (LLPCs) and memory B cells (MBCs), cell types canonically generated during germinal center (GC) reactions. ⋯ Importantly, GC responses strongly correlated with neutralizing antibody production. mRNA vaccines more efficiently induced key regulators of the Tfh cell program and influenced the functional properties of Tfh cells. Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses.

      read more… mark as read…

    • JAMA · Jun 2021

      Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.

      Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited. ⋯ In this exploratory analysis of a convenience sample, receipt of a COVID-19 mRNA vaccine was immunogenic in pregnant women, and vaccine-elicited antibodies were transported to infant cord blood and breast milk. Pregnant and nonpregnant women who were vaccinated developed cross-reactive antibody responses and T-cell responses against SARS-CoV-2 variants of concern.

      read more… or not…

    • Nature · Apr 2021

      mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

      Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-21-4. Eight weeks after the second injection of vaccine, volunteers showed high levels of IgM and IgG anti-SARS-CoV-2 spike protein (S) and receptor-binding-domain (RBD) binding titre. Moreover, the plasma neutralizing activity and relative numbers of RBD-specific memory B cells of vaccinated volunteers were equivalent to those of individuals who had recovered from natural infection5,6. ⋯ However, neutralization by 14 of the 17 most-potent monoclonal antibodies that we tested was reduced or abolished by the K417N, E484K or N501Y mutation. Notably, these mutations were selected when we cultured recombinant vesicular stomatitis virus expressing SARS-CoV-2 S in the presence of the monoclonal antibodies elicited by the vaccines. Together, these results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid a potential loss of clinical efficacy.

      expand abstract… or not…

    • Nature · Jun 2021

      SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.

      The presence of spike-protein binding B cells in axillary lymph nodes even 15 weeks after Pfizer BNT162b2 vaccination, suggests SARS-CoV-2 protection could last years after immunisation.

      pearl

      explore more… or just mark as read…

    • Nature · Jul 2021

      SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.

      Bone marrow plasma cells producing antibodies to the SARS-CoV-2 spike protein likely provide robust and long-lived immunity after mild COVID-19.

      pearl

      read more… or not…

    collapse collection…


Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
988,657 articles already indexed!

We guarantee your privacy. Your email address will not be shared.